Virologic and immunologic benefits of initial combination therapy with zidovudine and zalcitabine or didanosine compared with zidovudine monotherapy. Wellcome Resistance Study Collaborative Group (Q71120796)
Jump to navigation
Jump to search
scientific article published on 01 June 1996
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Virologic and immunologic benefits of initial combination therapy with zidovudine and zalcitabine or didanosine compared with zidovudine monotherapy. Wellcome Resistance Study Collaborative Group |
scientific article published on 01 June 1996 |
Statements
Virologic and immunologic benefits of initial combination therapy with zidovudine and zalcitabine or didanosine compared with zidovudine monotherapy. Wellcome Resistance Study Collaborative Group (English)
R T Schooley
C Ramirez-Ronda
J M Lange
D A Cooper
J Lavelle
L Lefkowitz
M Moore
B A Larder
M St Clair
J W Mulder
R McKinnis
K N Pennington
P R Harrigan
I Kinghorn
H Steel